Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment

CONCLUSION: Regarding risk-benefit assessment, OMA 300 mg emerges as the optimal pharmacological intervention for CU, while OMA 150 mg stands as a secondary alternative compared to H1 antihistamines and cyclosporine.PMID:37750025 | DOI:10.1080/14740338.2023.2262377

Source: Expert Opinion on Drug Safety - September 26, 2023 Category: Drugs & Pharmacology Authors: Tian Qian Xia Jiang Daojun Zhang Yao Song Fei Hao Source Type: research